Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced participation in two major upcoming conferences focused on healthcare. The 32nd Annual Piper Sandler Virtual Healthcare Conference is scheduled for December 1-3, 2020, where Avadel's management will present. Additionally, they will present at the 3rd Annual Evercore ISI HealthCONx Conference on December 3, 2020, at 9:15 a.m. ET. Webcasts for both events will be available on Avadel's website and through the conference sites.

The company's primary focus remains on developing FT218, a once-nightly formulation of sodium oxybate aimed at treating narcolepsy.

DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the 32nd Annual Piper Sandler Virtual Healthcare Conference and the 3rd Annual Evercore ISI HealthCONx Conference that are being held in December 2020.

Event:	32nd Annual Piper Sandler Virtual Healthcare Conference
Date:	December 1st - 3rd
Webcast:	A webcast presentation will be available via the Piper Sandler conference site (click here) from November 23rd to December 3rd. In addition, the webcast will be posted on Avadel’s website, www.avadel.com, for 90 days from being made available.
Event:	3rd Annual Evercore ISI HealthCONx Conference
Date:	Thursday, December 3rd
Time:	9:15 a.m. ET
Webcast:	A webcast will be available at (click here), as well as on the “Investors” section of the Company’s website at www.avadel.com. A replay of the webcast will be available on Avadel’s website for 90 days following the presentation.

About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.

Contacts:

	Tom McHugh
	Chief Financial Officer
	Phone: (636) 449-1843
	Email: tmchugh@avadel.com
	Tim McCarthy
	LifeSci Advisors, LLC
	Phone: (212) 915-2564
	Email: tim@lifesciadvisors.com

 

FAQ

What events is Avadel Pharmaceuticals participating in December 2020?

Avadel Pharmaceuticals will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference from December 1-3 and at the 3rd Annual Evercore ISI HealthCONx Conference on December 3, 2020.

What is FT218 from Avadel Pharmaceuticals?

FT218 is an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy.

When can I watch Avadel Pharmaceuticals' conference webcasts?

The webcasts for both conferences will be available from November 23 to December 3, 2020, and will be accessible on Avadel’s website for 90 days.

What is the time for Avadel's presentation at the Evercore ISI HealthCONx Conference?

Avadel's presentation at the Evercore ISI HealthCONx Conference is scheduled for December 3, 2020, at 9:15 a.m. ET.

Where can I find more information about Avadel Pharmaceuticals?

More information about Avadel Pharmaceuticals can be found on their website at www.avadel.com.